• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Celgene Corp

NASDAQ:CELG

$68.90 -$1.01 (-1.44%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

7 Biotech Stocks to Add to Your Portfolio

5/26/2012 by InvestorPlace

FTC, Senate probing blocking of generic drug companies, Washington Post says

5/23/2012 by Theflyonthewall.com

Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference

5/23/2012 by PharmiWeb.com - UK

Generic-drug makers’ complaints over brand-name access prompt investigations

5/22/2012 by The Washington Post - Washington DC

Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference

5/22/2012 by Business Wire

Three new rules for biopharma collaborations

5/21/2012 by Fierce Biotech

CEOs Under Pressure & Stock Picks

5/16/2012 by CNBC Video

Celgene Retains Neutral Rec - Analyst Blog

5/14/2012 by Zacks Investment Research

Celgene Retains Neutral Rec

5/14/2012 by Zacks Equity Research Analyst Blog

FDA issues alert on Celgene's cancer drug Revlimid

5/14/2012 by The San Diego Union Tribune - San Diego CA

Celgene (CELG) Unit Reports Publication of Three REVLIMID Studies in MM Patients

5/10/2012 by StreetInsider.com

Celgene's REVLIMID for multiple myeloma shows positive Phase III results

5/10/2012 by Theflyonthewall.com

New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma

5/10/2012 by Business Wire

Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

5/10/2012 by PR Newswire

Cramer's Plan for a Sell-Off

5/9/2012 by CNBC Video

Vertex Leads A Big Week For Biotechs

5/9/2012 by Investor's Business Daily

Celgene Sets The Stage For Patient Investors

5/8/2012 by Seeking Alpha

Celgene Corporation Drug Revlimid Increases Risk of Certain New Cancers

5/8/2012 by BioSpace

RW Baird to host a conference

5/8/2012 by Theflyonthewall.com

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers

5/7/2012 by NASDAQ

FDA issues safety announcement on Celgene's Revlimid

5/7/2012 by Theflyonthewall.com

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel

5/7/2012 by PharmiWeb.com - UK

Celgene names Thomas M. Moriarty as general counsel

5/7/2012 by Theflyonthewall.com

26 Drugs Facing FDA Approval in 2012

5/2/2012 by TheStreet.com

Epizyme, Celgene Collaborate on HMTs

5/1/2012 by Drug Discovery & Development

Senesco Technologies says Lenalidomide/SNS01-T effective in cancer model

5/1/2012 by Theflyonthewall.com

Celgene recent weakness a buying opportunity, says Rodman & Renshaw

4/30/2012 by Theflyonthewall.com

Celgene Reports Q1 Results: Seeing Further Upside

4/29/2012 by Seeking Alpha

Disappointed By Celgene's Q1? Take The Long View

4/27/2012 by Seeking Alpha

Separating the Bargains From the Busts

4/27/2012 by TheStreet.com

Epizyme Gets $90 Million in Epigenetics Partnership With Celgene Corporation

4/27/2012 by BioSpace

Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and Sotheby's Released By InvestorsObserver

4/27/2012 by PR Newswire

Hot Stocks Research for Electronic Arts, Celgene, QUALCOMM, Monster Worldwide, MetroPCS, and Chevron

4/27/2012 by PR Newswire

Celgene downgraded at BofA/Merrill

4/27/2012 by Theflyonthewall.com

Biotech Stock Mailbag: AVI, Aveo, Spectrum

4/27/2012 by TheStreet.com

Celgene's CEO Discusses Q1 2012 Results - Earnings Call Transcript

4/26/2012 by Seeking Alpha

Stock Market Today Logs Third Straight Gain

4/26/2012 by Investor's Business Daily

Celgene slips as 1Q results fall short of views

4/26/2012 by Canadian Business - Canada

Celgene Misses, Reaffirms

4/26/2012 by Zacks Equity Research Analyst Blog

Celgene Misses, Reaffirms - Analyst Blog

4/26/2012 by Zacks Investment Research
See More Articles...